Ginkgo Bioworks Holdings, Inc. filings document an operating company focused on cell engineering, autonomous lab services, and biological R&D tools. Form 8-K reports record operating and financial results, material-event disclosures, governance matters, the completed Biosecurity divestiture, and the classification of that former business within discontinued operations.
Proxy and capital-markets filings cover board and shareholder voting matters, executive compensation, equity awards, and governance practices. The filing record also describes Ginkgo's Class A common stock listed on the NYSE under DNA, registration-statement activity, at-the-market offering arrangements, material agreements, and related capital-structure disclosures.
Ginkgo Bioworks Holdings, Inc. officer Steve Coen reported a proposed sale of 766 Class A shares for October 19, 2026, through Fidelity Brokerage Services LLC, with an aggregate market value of $7,769.23. The shares are listed as acquired from the issuer through restricted stock vesting on October 16, 2026. The sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Ginkgo Bioworks Holdings, Inc. is the issuer on a Form 144 notice for a proposed sale of 18,803 Class A shares for Canton Barry’s account; the form identifies Canton Barry as an officer. The approximate sale date is October 19, 2026, with Fidelity Brokerage Services LLC listed as broker and NYSE as the exchange. The shares are shown as acquired through restricted stock vesting on October 16, 2026, and the remarks say the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. Wade Moss signed as Fidelity’s authorized representative and attorney-in-fact for Bartholomew Canton.
Ginkgo Bioworks Holdings, Inc. (DNA) officer Che Austin gave notice of a proposed sale of 16,058 Class A shares through Fidelity Brokerage Services LLC, with an aggregate market value of $162,869.87 and an approximate sale date of October 19, 2026. The sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. During the prior three months, Che Austin reported sales of 2,200 shares on August 17, 2026, and 2,200 shares on September 17, 2026.
Ginkgo Bioworks Holdings, Inc. (DNA) is the issuer in a notice listing officer and director Reshma Shetty’s proposed sale of 22,369 Class A shares, with an aggregate market value of $226,879.82. The notice lists October 19, 2026, as the approximate sale date and Fidelity Brokerage Services LLC as broker, with NYSE named as the exchange. The shares were acquired through restricted stock vesting on October 16, 2026; the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Ginkgo Bioworks Holdings, Inc. officer and director Jason Kelly reported a proposed sale of 45,682 Class A shares through Fidelity Brokerage Services LLC, with an aggregate market value of $463,334.25 and an approximate sale date of October 19, 2026. The shares were acquired through restricted stock vesting on October 16, 2026. Kelly stated that the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Ginkgo Bioworks Holdings, Inc. officer Che Austin reported a proposed sale of 2,200 Class A shares, with an approximate sale date of October 19, 2026, and an aggregate market value of $22,836.00. Fidelity Brokerage Services LLC is listed as the broker. The notice lists earlier sales by Che Austin of 2,200 shares on August 17, 2026, for $14,652.00, and 2,200 shares on September 17, 2026, for $16,038.00. The shares proposed for sale are listed as restricted stock vesting from the issuer on November 11, 2022, for compensation.
Ginkgo Bioworks Holdings, Inc. Chief Financial Officer Steven P. Coen sold 2,403 shares of Class A Common Stock at $15 per share on October 5, 2026. He held 49,448 shares directly following the sale. The shares were sold pursuant to a sales plan adopted by Coen and intended to comply with Rule 10b5-1.
Ginkgo Bioworks Holdings, Inc. officer Steven P. Coen reported a proposed sale of 2,403 Class A shares through Fidelity Brokerage Services LLC, with an aggregate market value of $36,045.00 and an approximate sale date of October 5, 2026. NYSE is listed as the exchange for the proposed sale, and the reported Class A shares outstanding count is 55,383,808.
Ginkgo Bioworks Holdings, Inc. (DNA) has a notice of proposed sale under Rule 144 filed for officer Che Austin. The filing covers the potential sale of 2,200 Class A shares through Fidelity Brokerage Services LLC, with an aggregate market value of $16,038, against 55,383,808 Class A shares outstanding as of September 17, 2026. The shares derive from restricted stock vesting grants, and a prior sale of 2,200 Class A shares for $14,652 on August 17, 2026 is also disclosed.
Ginkgo Bioworks Holdings, Inc. (DNA) director Henry Christian O reported selling 5,000 shares of Class A Common Stock on September 15, 2026 in an open-market or private transaction at a weighted average price of $7.081 per share. After this sale, he holds 19,310 shares directly. No Rule 10b5-1 trading plan is indicated.
The filing notes the shares were sold in multiple trades at prices ranging from $7.074 to $7.085 per share, and the reporting person has undertaken to provide full breakdowns of the individual trade prices and sizes upon request.